TRPV4 and pulmonary edema: Trpv4 is recognised as a druggable target in pulmonary edema and congestive heart failure; however, so far, only GSK2798745, a Trpv4 antagonist, has entered clinical trials (Thorneloe et al., 2012; Lawhorn et al., 2021).